Press Room

RDD 2021

Start
Tuesday, May 04, 2021 - 00:00
End
Friday, May 07, 2021 - 00:00
Location: online
Continuous Manufacturing Drug Product Commercial Supply | Hovione

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with us.

 

steve-landelius-photo

Steven Landelius

Business Development Manager

 

 

Schedule a meeting button | Hovione

From May 4-7, do not miss Hovione's Scientists Presentations at RDD 2021 virtual conference.

 

WORKSHOP
PRESENTATION

Fully Integrated DPI Development – From API To Device
João Pereira and Beatriz Noriega Fernandes

 

What will you learn?
  • How to choose a suitable API formulation
  • How to select the right particle engineering technology
  • Novel techniques for inhalation products characterization
  • Advanced solutions for inhalation platforms

POSTERS

Comparison of Two Drug Micronization Methods Using Multiple Physiochemical Characterization Techniques
Sara Perico

 

Understanding Particle Friability Through Solid State Characterization
Ruben Chaves

ABSTRACTS

Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Performance Studies
Patricia Henriques

 

Our experts are available to listen and understand your projects. Together we can speed up your Inhalation drug development, with less regulatory hurdles, less time, and less costs.

 

 
Drug Product Facility in Portugal | Hovione

 

 

Hovione Inhalation Development Virtual Tour (click on the image to watch video)

Meet Eunice Costa, Hovione’s group leader for Inhalation Development and visit the site where all the team sits together.

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025